IBR Inc. is a Swiss contract research organisation with a core
competence in inflammation research and over 10 years experience of
providing preclinical and clinical R&D services to
biotechnology and pharmaceutical companies. A multidisciplinary
team of scientists, GLP-compliant laboratories and a broad pattern
of validated methods cover the drug development process from early
lead optimization to clinical studies. Ensuring access to expert
knowledge in all phases of the drug development process, IBR Inc.
provides cutting edge bioanalytical services, while meeting
the regulatory specifications and the time schedule of its
customers. IBR Inc. provides method development for preclinical R&D
covering drug characterization, mode of action, pharmacology,
preclinical safety evaluation, immune-profiling and cell based
assays. In clinical R&D, IBR Inc. provides method development,
validation and performance of sample analysis.